Jazz Pharmaceuticals (JAZZ) Expected to Announce Quarterly Earnings on Wednesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) will likely be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect Jazz Pharmaceuticals to post earnings of $5.83 per share and revenue of $1.06 billion for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $135.39 on Wednesday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a 1 year low of $99.06 and a 1 year high of $138.27. The company has a market capitalization of $8.19 billion, a PE ratio of 19.07, a P/E/G ratio of 0.92 and a beta of 0.56. The company has a fifty day moving average of $123.73 and a two-hundred day moving average of $117.41.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the transaction, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders sold 5,053 shares of company stock valued at $617,442. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on JAZZ. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Robert W. Baird increased their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. TD Cowen decreased their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $180.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.